Invivyd, Inc.
NASDAQ:IVVD · NASDAQ Global Market
+$0.04 today
Vol 14.12M · Avg 3.62M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$52.5M +69.1% | -$169.9M +14.5% | -$198.6M +17.7% | -$241.3M -6.4% | -$226.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $2.1M -32.3% | $3.1M +53.5% | $2.0M +339.0% | $462.0K +46100.0% | $1.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $11.6M -41.2% | $19.8M +5.9% | $18.7M -13.7% | $21.6M +21.9% | $17.8M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$19.7M +16.1% | -$23.5M -498.6% | $5.9M +136.5% | -$16.1M -170.8% | $22.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$3.3M +69.4% | -$10.9M | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | -$373.0K +98.5% | -$24.9M | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.2M +32.5% | $2.4M -62.6% | $6.5M +250.5% | -$4.3M -81.4% | -$2.4M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$19.2M -293.8% | $9.9M +1799.0% | -$583.0K +95.1% | -$11.8M -147.0% | $25.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $298.0K -98.5% | $19.8M +1863.6% | -$1.1M -107.3% | $15.3M +926.1% | $1.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$58.1M +65.9% | -$170.5M +1.5% | -$173.2M +21.3% | -$220.0M -19.1% | -$184.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$155.0K -10.7% | -$140.0K +77.2% | -$615.0K +63.9% | -$1.7M -1929.8% | -$84.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 +100.0% | -$91.2M +69.4% | -$298.0M -58.0% | -$188.6M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 -100.0% | $372.5M +439.9% | $69.0M -50.0% | $138.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$155.0K -10.7% | -$140.0K -100.0% | $280.7M +221.7% | -$230.7M -354.9% | -$50.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $215.6M +448.9% | $39.3M +3187.4% | $1.2M +134.3% | $510.0K -99.8% | $330.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 +100.0% | -$1.0K +75.0% | -$4.0K | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $46.0K -95.6% | $1.0M +105.1% | $510.0K +115.1% | -$3.4M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $215.6M +448.2% | $39.3M +3663.7% | $1.0M +106.5% | $506.0K -99.9% | $662.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 -100.0% | $8.0K | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $157.3M +219.8% | -$131.3M -220.9% | $108.6M +124.1% | -$450.1M -205.4% | $427.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$58.3M +65.8% | -$170.6M +1.8% | -$173.8M +21.6% | -$221.7M -20.0% | -$184.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.17B
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$334.23M
OmniAb, Inc.
NASDAQ:OABI
$259.52M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$233.54M
Codexis, Inc.
NASDAQ:CDXS
$225.88M
Protara Therapeutics, Inc.
NASDAQ:TARA
$154.55M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$146.29M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$99.38M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$72.83M
SEC Filings
Recent regulatory filings
No filings found.
Does IVVD generate free cash flow?
Invivyd, Inc. (IVVD) generated -$58,290,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does IVVD produce?
Operating cash flow was -$58,135,000.00, before capital expenditures of $155,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.